Print this article
- 12/02/2020

The UK has granted emergency approval for Pfizer/BioNTech’s covid-19 vaccine

Chimica Oggi-Chemistry Today

The news: The UK’s regulator has approved Pfizer/BioNTech’s vaccine, making it the first country in the world to provide emergency authorization for a covid-19 vaccine. The UK had already signed an agreement to buy 40 million doses due to be delivered this year and in 2021, with the first batch set to arrive in the coming days. The vaccine requires two doses, so that is enough for 20 million people. The vaccine will be delivered in stages to each country that has bought it, in order to make sure the doses can be allocated fairly, the two companies said. The US and EU are expected to provide emergency authorizations for vaccines in December too.

The basis for the decision: The UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) studied Pfizer and BioNTech’s data on a rolling basis as it came in from the trials, including data from the phase 3 clinical trial, which found the vaccine to be 9

A project like no other: Now that the vaccine has been approved, the enormous task of distribution can start. A particular challenge is that it needs to be kept at -70 °C. Pfizer and BioNTech have developed containers that use dry ice to keep the vaccine at these ultra-cold temperatures. The UK is on the precipice of the biggest vaccination campaign in its history. Its government has drawn up plans to start immunizing elderly and vulnerable patients within days. It has drafted a priority list, which starts with care home residents, people over 80, and health and social care workers. When more stocks become available, the UK will start vaccinating everyone over 50, as well as younger people with preexisting conditions. Its National Health System will contact people to invite them for the shot when it is their turn.

www.technologyreview.com